期刊文献+

碘氟醇在冠心病伴轻度慢性肾功能不全患者中的应用 被引量:2

Application of ioversol in mild chronic renal insufficiency patients with coronary heart disease
下载PDF
导出
摘要 目的比较碘氟醇与碘克沙醇在冠心病伴轻度慢性肾功能不全患者介入术后对肾功能的影响,并探讨碘氟醇应用的安全性。方法选择冠心病伴轻度肾功能不全[即肾小球滤过率(GFR)介于60~90ml/1.73m2·min]的患者60例,根据冠状动脉介入诊疗应用造影剂的不同,随机分为等渗组(n=30,应用碘克沙醇)和低渗组(n=30,应用碘氟醇),比较两组介入治疗后肾小球虑过率(GFR)的差异。结果两组患者年龄、肾功能、血红蛋白及术中造影剂用量无差异(P〉0.05),术后24小时及3、7天的肾小球滤过率也无统计学差异(P〉0.05)。结论碘氟醇在冠心病伴轻度慢性肾功能不全患者中的应用是安全的,造影效果与碘克沙醇无明显差异,但价格便宜,可在临床推广应用。 Objective To compare effect of ioversol and iodixanol on renal function after intervention operation in mild chronic renal insufficiency patients with coronary heart disease and explore the safety of ioversol application in the patients.Methods 60 coronary heart disease patients with mild renal insufficiency(GFR between 60-90 ml/min 1.73m2)were randomly divided into isotonic group treated with iodixanol(n=30)and low permeability group treated with ioversol(n=30).GFR after intervention operation was observed.Results The age,renal function,hemoglobin and contrast agent dosage of the two groups had no difference.The GFR of the two groups after 24 hours,3days,7days of the intervention operation had no statistical difference(P〉0.05).Conclusion Application of ioversol in mild chronic renal insufficiency patients with coronary heart disease is safe and cheaper which has the same imaging effect as iodixanol.
出处 《西部医学》 2015年第3期408-409,411,共3页 Medical Journal of West China
关键词 碘氟醇 碘克沙醇 心脏介入 肾小球滤过率(GFR) Ioversol Iodixanol Cardiac intervention therapy Glomerular filtration rate
  • 相关文献

参考文献10

  • 1Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency [J]. AmJ Kidney Dis, 2002,39:930-936.
  • 2Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary in- tervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creati- nine[J]. Catheter Cardiovasc Interv, 2003,59 : 338-343.
  • 3Mchran R,Aymong ED,Nikolsky E,et al. A simple resk score for prediction of contrast-induced nephropathy after percutane- ous coronary intervention:development and initial validation[J]. J Am Coil Cardiol, 2004,44 : 1393-1399.
  • 4Lindsay J,Canos DA,Apple S,et al. Causes of acute renal dys- function after percutaneous coronary intervention and compari- son of late mortality rates with postprocedure rise of creatine ki- nase-MB versus rise of serum creatinine[J]. Am J Cardiol, 2004,94:786-789.
  • 5Rudnick MR, Goldfarb S. Pathogenesis of contrast-inducednephropathy: experimental and clinical observations with an em- phasis on the role of osmolality[J]. Rev Cardiovasc Med, 2003, 4 Suppl 5:S28-33.
  • 6Seeliger E, Becker K, et al. Up to 50-fold increase in urine vis- cosity with iso-osmolar contrast media in the rat[J]. Radiology, 2010 Aug,256(2) :406-414.
  • 7Glenn N, et al. 2011 ACCF/AHA/SCAI Guideline for Percutane- ous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J]. Circulation, 2011,124 : 2005-2011.
  • 8Weisbord SD,Palevsky PM. Prevention of contrast-induced ne-phropathy with volume expansion[J]. Clin J Am Soc Nephrol, 2008,3: 273-280.
  • 9Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotox- icity of high- and low-osmolality iodinated contrast media [J]. Radiology, 1993,188(1) :171-178.
  • 10Wright RS, Anderson JL, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Up- dating the 2007 Guideline) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [J]. Circulation, 2011,123 (18) : 2022- 2060.

同被引文献19

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部